DJS Antibodies Revenue and Competitors

Oxford,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • DJS Antibodies's estimated annual revenue is currently $3.3M per year.(i)
  • DJS Antibodies's estimated revenue per employee is $155,000

Employee Data

  • DJS Antibodies has 21 Employees.(i)
  • DJS Antibodies grew their employee count by 5% last year.

DJS Antibodies's People

NameTitleEmail/Phone
1
Director, ResearchReveal Email/Phone
2
Managing DirectorReveal Email/Phone
3
DirectorReveal Email/Phone
4
Senior Research AssociateReveal Email/Phone
5
Research AssociateReveal Email/Phone
6
ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is DJS Antibodies?

At DJS we are developing novel therapeutics to treat chronic inflammatory diseases. We do this through the discovery and development of novel therapeutic monoclonal antibodies against GPCRs. Our breakthrough technology enables us to produce first-in-class antibody therapeutics to previously intractable disease targets.

keywords:N/A

N/A

Total Funding

21

Number of Employees

$3.3M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

DJS Antibodies News

2022-04-17 - Vitamin B6 deficiency: Symptoms including tiredness and skin rashes and long term effects

In particular, a B6 deficiency can stop your body from producing vital antibodies that are needed to fight off infection and disease.

2022-04-06 - Russia, Twitter, Marijuana: Your Thursday Evening Briefing

... the level of neutralizing antibodies against multiple strains of ... waiting in line with D.J.s, doughnut trucks and steel drum bands.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.1M21-5%N/A
#2
$1.5M21-40%N/A
#3
$2.2M21N/AN/A
#4
$1.5M21-9%N/A
#5
$3.4M225%N/A